Fed’s Powell opens door to potential rate cuts at Jackson Hole
Jean F. Holloway, Senior Vice President and General Counsel at Artivion, Inc. (NYSE:AORT), a $1.23 billion medical device company, sold 9,926 shares of the company’s common stock on May 21, 2025. The timing of this sale comes as InvestingPro data shows the stock trading near its 52-week high of $32.33, with technical indicators suggesting overbought conditions. The shares were sold at a price of $29 each, amounting to a total transaction value of $287,854. Following this transaction, Holloway retains ownership of 187,258 shares in the company. The stock has shown strong momentum with a 24% return over the past year, though current valuation metrics suggest premium pricing with elevated EBIT and EBITDA multiples.
In other recent news, Artivion Inc. reported its first-quarter earnings for 2025, revealing a revenue of $99 million, which fell short of the anticipated $104.65 million. However, the company’s earnings per share (EPS) exceeded forecasts, coming in at $0.06 against an expectation of $0.0003. Additionally, Artivion announced agreements to repurchase approximately $95 million in principal amount of its 4.250% Convertible Senior Notes due 2025, exchanging them for common stock. This move is part of the company’s strategy to manage its debt.
At the company’s 2025 Annual Meeting of Stockholders, Artivion’s shareholders approved the compensation of its named executive officers and additional equity funding for its 2020 Equity and Cash Incentive Plan. Furthermore, JMP Securities maintained a Market Outperform rating for Artivion, with a $33 price target, following the company’s earnings report. Stifel analysts also kept a Buy rating with a $30 price target, noting the company’s strong performance despite previous challenges from a cybersecurity breach. Artivion’s management has updated their expectations, projecting that a tissue backlog will be cleared by the third quarter of 2025, indicating progress in overcoming supply chain hurdles.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.